ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA)

ProShare Advisors LLC lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 9.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 401,548 shares of the company’s stock after selling 43,073 shares during the period. ProShare Advisors LLC’s holdings in Moderna were worth $47,684,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of MRNA. Vanguard Group Inc. raised its stake in shares of Moderna by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after purchasing an additional 5,129,800 shares in the last quarter. Wellington Management Group LLP lifted its stake in Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after acquiring an additional 1,614,460 shares during the last quarter. Capital World Investors grew its position in shares of Moderna by 0.5% in the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after acquiring an additional 18,728 shares during the period. Mawer Investment Management Ltd. increased its stake in shares of Moderna by 6.7% during the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock worth $204,230,000 after purchasing an additional 120,621 shares during the last quarter. Finally, Bellevue Group AG raised its holdings in shares of Moderna by 27.6% in the 4th quarter. Bellevue Group AG now owns 1,908,420 shares of the company’s stock valued at $189,792,000 after purchasing an additional 413,095 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the sale, the director now directly owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The sale was disclosed in a filing with the SEC, which is available through this link. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the transaction, the director now owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,158 shares of company stock worth $11,167,312. Insiders own 15.70% of the company’s stock.

Moderna Trading Down 3.4 %

Shares of Moderna stock opened at $65.69 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a market capitalization of $25.18 billion, a price-to-earnings ratio of -4.19 and a beta of 1.67. The firm’s 50-day moving average price is $90.07 and its two-hundred day moving average price is $110.96.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same quarter last year, the business posted ($3.62) EPS. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. On average, analysts forecast that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRNA has been the topic of a number of recent analyst reports. TD Cowen lowered their price target on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Bank of America decreased their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Piper Sandler cut their target price on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. The Goldman Sachs Group decreased their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Finally, Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $100.44.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.